On Mar. 12, 2026, Mass General Brigham (MGB) announced it has received a $50 million gift that will shape the future of cancer care and discovery by empowering the next generation of gene and cell therapy research. The gift, made by anonymous donors, will advance clinical research by experts at Mass General Brigham Cancer Institute and throughout the system, to deliver life-changing treatments for patients with cancer and other diseases.

Mass General Brigham is accelerating progress to advance its bold vision for the future of cancer care, building research and clinical spaces, elevating quality to save more lives every year, and investing in a multidisciplinary approach to care that places patients at the center. With this gift, the system will build on its national leadership in research by continuing to fund physical spaces, experts and programs that support gene and cell therapies. This includes facilities for apheresis and a cell pharmacy.

With the power of the nation’s largest hospital-based research enterprise, Mass General Brigham Cancer Institute is shaping the future of cancer care through research, including gene and cell therapies. Mass General Brigham researchers recently announced exciting results of a clinical trial using CAR T-cell therapy to treat glioblastoma.

Gene therapy involves the use of genetic material to affect how cells produce proteins which may more effectively fight disease or reduce its presence. Cell therapy derives from the use of intact human cells—from a patient or donor—that replace or repair damaged cells to help fight disease. These treatments have also transformed care for patients with leukemia and other cancers, and show great promise in treating lung diseases, autoimmune diseases, stroke, neurodegenerative diseases, spinal cord injuries and more.

The anonymous donors make this commitment with deep gratitude for the compassionate and expert care provided by staff across Mass General Brigham. Accordingly, their gift will invest in physician-scientists who are transforming genes and cells into living treatments and support the recruitment of global leaders in the field.